We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

REDX Redx Pharma Plc

0.00 (0.00%)
15 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 15.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
12.00 17.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 15.00 GBX

Redx Pharma (REDX) Latest News

Redx Pharma (REDX) Discussions and Chat

Redx Pharma Forums and Chat

Date Time Title Posts
30/4/202409:32Redx Pharma PLC554
02/7/202008:39REDX Pharma Discussion Thread Moderated157

Add a New Thread

Redx Pharma (REDX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Redx Pharma (REDX) Top Chat Posts

Top Posts
Posted at 05/4/2024 15:12 by pre
another one to delist - near certainty to delist as they already have way over 75% approval to cancel listing as per rns on 2/4/24, extract below:

As at today's date, the Company has received letters of intent and irrevocable undertakings from certain Shareholders representing approximately 84.64 per cent. of the Company's issued share capital to vote in favour of the Resolutions.
Posted at 26/3/2024 18:44 by muchodinero
If you read through the Jazz results it mentions the Redx Pharma deals under heading Business Updates/Corporate Development

........."KRAS Inhibitor Program Agreement:

In February 2024, the Company acquired Redx Pharma's KRAS inhibitor program, which includes G12D selective and pan-KRAS molecules, further expanding Jazz's early-stage oncology pipeline.".......
Posted at 26/3/2024 15:39 by muchodinero
Jazz Pharma post record sales for 2023 including over $1 billion 4th Qtr sales for first time. Great set of results for Jazz Pharma and includes mention of buying rights to Redx Kras inhibitor in the results. A great global Pharma partner for Redx it appears and potential $870 million in milestone and future royalty payments in the future. Also payments to Redx for future development work on KRAS programme as well it seems? GLA Adyor!
Posted at 15/2/2024 07:21 by bermudashorts

Redx have another $15m in potential near term milestones from the previous deals with Jazz and AstraZeneca.
Posted at 23/2/2023 09:18 by pejaten
umm. terms seem unfair to REDX
Posted at 04/9/2022 14:59 by knitcraft
Put RXC004 into your search Engine then refer to my last post.

It gives real hope for specialist cancer and fibrosis treatment of previously extremly hard to treat tumours.

.....and potentially will give you the opportunity to buy into RedX before the news is widely available as to just who is responsible for this potential life-saving research.
Posted at 04/9/2022 14:37 by knitcraft
The following news item was first published in The "I" last week and has been subsequently picked up by other publications and TV news. The link below is to an ITV news item.

The intriguing and very important information that is missing from all the items, is the name of the company doing the research on RXC004.

It happens to be RedX and when that fact becomes widely known I would expect a reassessment of the value of RedX.

In June Trinity Delta,a reputable research company specialising in biomedicals, valued RedX shares on an undiluted basis at £1.38. The share price is currently 60p. Redx has at least 4 very promising research streams on the go.

From the research note in June 2022
Redx Pharma continues to deliver, with H122 results highlighting broad progress across the pipeline. The lead assets, RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are advancing through Phase II and Phase I trials respectively, with further value inflection expected during 2022-23. Milestone receipts from AstraZeneca and Jazz Pharmaceuticals are tangible evidence of further progress with partnered programmes. Selection of RXC008, a GI targeted ROCK inhibitor as the next development candidate demonstrates earlier stage development is similarly bearing fruit. Our new rNPV-based valuation, updated to reflect H122 results and the May £34.3m (gross) equity raise, is £458m (vs £434m), or 138p/share.

It is worth looking at the company in more detail to fully appreciate what they are about. Look at the highly qualified team that has been assembled. Also check the lines of research they are pursuing and the major pharmaceutical companies they are associated with.
Also have look at the major shareholders involved.

Now look at this. Very few know this is about RedX. I suspect they soon will!
Posted at 09/12/2021 08:29 by wapper
UK, 9 December 2021 - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that a milestone payment from Jazz Pharmaceuticals (NASDAQ: JAZZ) has been triggered as a result of entering the second year of the oncology research collaboration with the Company.

The milestone payment of $10 million arises in accordance with the terms of the research collaboration agreement announced on 9 September 2020. Under the agreement to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway, Redx is responsible for research and preclinical development activities up to Investigational New Drug (IND) submission. In addition to the $20 million in payments that have now been realised, Redx may receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each programme. The next milestone is payable upon successful IND submission and all subsequent milestones are contingent on successful completion of the relevant stages of development. In addition, Redx is eligible for tiered royalties in mid-single digit percentages, based on any future net sales.

Lisa Anson, Chief Executive Officer of Redx, commented: "We are extremely pleased to extend our productive oncology research collaboration with Jazz into its second year. This is based on advancing our programmes in this key signalling pathway and reflects Redx's core strength in discovering highly targeted potential drug candidates. We look forward to further progress in partnership with Jazz."

Redx continues to execute on its strategy, progressing its lead oncology and fibrosis programmes. These include the oral Porcupine inhibitor, RXC004, targeting Wnt-ligand driven tumours, which has recently entered a Phase 2 trial in genetically selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) and the oral selective ROCK2 inhibitor, RXC007, being developed for idiopathic pulmonary fibrosis, where first in human studies commenced in June 2021.
Posted at 10/9/2021 19:08 by knitcraft
Any update amrish? I think we would all appreciate your views on the future of Redx and it’s share price
Posted at 19/8/2020 18:46 by kennylogsin
Supercity - thanks for pointing out the 92% holding. I was running from the email alert issued by HL yesterday which opened with: Our Reference: 02648800

RedX Pharma plc - Your holding of xx,xxx Shares

Extended Cash Offer - Important information that requires your attention

What is happening?
Redmile Group recently bought approximately 39.5% of the RedX Pharma plc shares in issue at a price of 15.5p per share. Under UK company law the company has to offer to buy all remaining RedX shares at the same price. As a holder of RedX Pharma plc Shares in your Hargreaves Lansdown Stocks & Shares ISA you need to decide whether you wish to accept the Offer or not. At the time of writing RedX Pharma plc Shares are trading at 45p so you may get less cash by accepting this offer than you would trading your Shares in the market.

The other part I stated was at the bottom of the communication:
What happens if I do not accept the Offer?
If Redmile is able to obtain acceptances for 90% of the Company's Shares then they can force all remaining Shareholders to sell their Shares at the offer price. Redmile has indicated that if it receives acceptances in excess of 90% it does not currently intend to exercise its rights to compulsorily acquire the remaining RedX Pharma plc Shares.

If the Company receives acceptances in excess of 90% and does move to compulsorily acquire the remaining Shares, we will put forward your holding for acceptance of the Offer, as long as it remains open, in order to ensure that you receive proceeds in respect of your holding as soon as possible. If not you will receive the proceeds once the Compulsory Acquisition has been completed.

Redmile has stated that it intends to maintain RedX Pharma plc’s listing on AIM. However, if AIM is no longer considered a suitable market for RedX shares, Redmile may seek to move to a different market or trading facility.

Super - as I got this yesterday how is it 8 week old information? Was something issued somewhere else? Any advice welcome...
Redx Pharma share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock